• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Report: Outlook for pediatric drug development looks promising

Report: Outlook for pediatric drug development looks promising

November 18, 2016
CenterWatch Staff

Resources dedicated to creating medicines to meet the unique needs of children have grown steadily since legislation guiding pediatric drug development was enacted in the U.S. two decades ago, and the outlook for still greater development looks promising, according to a new analysis completed by the Tufts Center for the Study of Drug Development.

Even though R&D complexity has grown more than 50% since 2008, resources dedicated to pediatric studies have increased across most R&D functions, according to the new Tufts CSDD study, which updates a similar assessment it completed nearly a decade ago.

"Much has changed since 2007, including the need to conduct pediatric studies earlier in development across all age groups, with appropriate formulations, in the context of a changing, more complex research environment," said Christopher-Paul Milne, research associate professor and director of research at Tufts CSDD at Tufts University School of Medicine, who conducted the analysis.

Since the Best Pharmaceuticals for Children Act (BPCA) and the Pediatric Research Equity Act (PREA) were enacted in 2002 and 2003, respectively, more than 600 drugs and biologicals originally developed for adults have been labeled in the U.S. with specific information to inform safer administration and dosing in children.

"Developing formulations for children was not achieved easily and remains a costly and complex undertaking," said Milne.

He noted that pediatric R&D today must account for expanded data requirements and changes imposed by advances in pharmacogenomics, regulatory science, and multi-country clinical trial networks.

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • SurveywBlueBackground-360x240.png

    Sites Name Tech Acceptance as Essential Factor in Selection of Sponsors, Survey Finds

  • TrendsInsights2023-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Two

  • TimeMoneyEffort-360x240.png

    Time is Money and So Is Effort, Budgeting Experts Say

  • TrendsInsights2023A-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Three

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing